Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer

Despite the recent emergence of immune checkpoint inhibitors, clinical outcomes of metastatic NSCLC patients remain poor, pointing out the unmet need to develop novel therapies to enhance the anti-tumor immune response in NSCLC. In this regard, aberrant expression of the immune checkpoint molecule C...

Descripción completa

Detalles Bibliográficos
Autores principales: Flieswasser, Tal, Van den Eynde, Astrid, Freire Boullosa, Laurie, Melis, Jöran, Hermans, Christophe, Merlin, Céline, Lau, Ho Wa, Van Audenaerde, Jonas, Lardon, Filip, Smits, Evelien, Pauwels, Patrick, Jacobs, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038060/
https://www.ncbi.nlm.nih.gov/pubmed/36970072
http://dx.doi.org/10.1080/2162402X.2023.2192100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038060/
https://www.ncbi.nlm.nih.gov/pubmed/36970072
http://dx.doi.org/10.1080/2162402X.2023.2192100

Ejemplares similares